Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

The REACH Trial Investigators

Research output: Contribution to journalArticlepeer-review

401 Citations (Scopus)

Fingerprint Dive into the research topics of 'Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences